36566 Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices 

11, 2015, [HHS Ref. No. E–050–2015–0– 

US–01]; 

II. International Patent Application 

No. PCT/US2016/022072 filed Mar. 11, 

2015, [HHS Reference No. E–050–2015– 

0–PCT–03]; expired 

III. Australian National Stage Patent 

Application No. 2016228751, filed Mar. 

11, 2016, [HHS Ref. No. E–050–2015–0– 

AU–04]; pending 

IV. Canadian National Stage Patent 

Application No. 2979229 filed Mar. 11, 

2016, [HHS Ref. No. E–050–2015–0– 

CA–05]; pending 

V. European national Stage Patent 

Application No. 1662623.3 filed Oct. 11, 

2016, [HHS Ref. No. E–050–2015–0–EP– 

06]; issued (validated in DE, FR and GB) 

VI. U.S. national Stage Patent 

Application No. 15/556,746 filed Sep. 8, 

2017 [HHS Ref. No. E–050–2015–0–US– 

08]; issued 

VII. Japanese National Stage Patent 

Application No. 2017–547425 filed Sep. 

8, 2017 [HHS Ref. No. E–050–2015–0– 

JP–07]; pending 

VIII. Divisional European Patent 

Application No. 20176667.2 filed May 

26, 2020 [HHS Ref. No. E–050–2015–0– 

EP–13]; pending 

IX. Divisional Japanese Patent 

Application No. 2020–167984 filed Oct. 

2, 2020 [HHS Ref. No. E–050–2015–0– 

JP–14]; pending 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to: 

‘‘Development and commercialization 

of RP2 AAV-based gene human therapy 

for any ocular disease, disorder or 

condition, including human X-linked 

retinitis pigmentosa (XLRP)’’. 

This technology discloses AdenoAssociated Viral (AAV) vectors 

comprising nucleotide sequences 

encoding RP2 or RPGR- ORF 15 

transgenes and their use in treating or 

preventing X-linked forms of retinitis 

pigmentosa (XLRP). 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: July 2, 2021. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2021–14682 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Center for Scientific 

Review Special Emphasis Panel; Member 

Conflict: Motor function in healthy and 

clinical populations. 

Date: August 3, 2021. 

Time: 1:00 p.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Maribeth Champoux, 

Ph.D., Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 3170, 

MSC 7848, Bethesda, MD 20892, 301–594– 

3163, champoum@csr.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: July 6, 2021. 

David W. Freeman, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–14697 Filed 7–9–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary & 

Integrative Health; Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Complementary and 

Integrative Health. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations, should notify the 

Contact Person listed below in advance 

of the meeting. The Open Session will 

be open to the public via NIH Videocast. 

The URL link to access this meeting is 

https://videocast.nih.gov. 

Name of Committee: National Advisory 

Council for Complementary and Integrative 

Health. 

Date: September 10, 2021. 

Closed: 10:00 a.m. to 11:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Democracy 2, 6707 Democracy Boulevard, 

Bethesda, MD 20817 (Virtual Meeting). 

Open: 11:40 a.m. to 5:00 p.m. 

Agenda: A report from the Director of the 

Center and Other Staff. 

Place: National Institutes of Health, 

Democracy 2, 6707 Democracy Boulevard, 

Bethesda, MD 20817 (Virtual Meeting). 

Contact Person: Partap Singh Khalsa, 

Ph.D., DC, Director, Division of Extramural 

Activities, National Center for 

Complementary and Integrative Health, 

National Institutes of Health, 6707 

Democracy Blvd., Suite 401, Bethesda, MD 

20892–5475, 301–594–3462, khalsap@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 


khammond on DSKJM1Z7X2PROD with NOTICES